A Phase 1 interventional study of Digoxin and Vemurafenib in Malignant Melanoma, Neoplasms, sponsored by Hoffmann-La Roche. Completed at 13 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-23.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies testing vemurafenib in Melanoma — 2 open to participants now, 2 under way, 1 of them phase 3. Vemurafenib · Melanoma.
Among the 56 studies testing vemurafenib in Melanoma, this one is the 22nd largest by enrollment, is one of 18 that started in 2013, is one of 26 in phase 1, and was the 26th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →2 of the 56 studies testing vemurafenib in Melanoma are open now, in 2 countries. Recruiting first, the newest first:
Cancer Research UK · Sites in United Kingdom
Ages 18+
University of Louisville · Sites in United States
Ages 18+
By country, each count listing its studies:
Vemurafenib: first FDA approval 2011 (ZELBORAF), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 25 · Phase 3 5 · Phase 4 1
First in 2006; this study’s year is marked. 18 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 18 across the 56 interventional studies. Of the 49 that completed or were terminated, 30 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 56 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
57 studies in Melanoma by Hoffmann-La Roche: none open now, 4 under way, none of them phase 3. Of 52 finished, 34 (65%) have results posted.
Among the 57 studies in Melanoma by Hoffmann-La Roche, this one is the 35th largest by enrollment of the 52 interventional ones that give a count, is one of 12 that started in 2013, is one of 27 in phase 1, and was the 23rd registered.
Hoffmann-La Roche’s Melanoma studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 56 studies testing vemurafenib in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 57 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, multi-center, three-period, one sequence study will investigate the effect of vemurafenib on the pharmacokinetics of digoxin in patients with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a V600-activating mutation of BRAF without acceptable standard treatment options. Patients will receive multiple doses of vemurafenib in Periods B and C and a single dose of digoxin in Periods A and C. Eligible patients will have the option to continue treatment with vemurafenib as part of an extension study (NCT01739764). The anticipated time on study treatment is approximately 36 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of digoxin 0.25 mg tablet on Day 1 in Period A, followed by vemurafenib 960 mg tablet orally BID from Day 8 to Day 28 in Period B, and then single oral dose of digoxin 0.25 mg on Day 29, and vemurafenib 960 mg orally BID from Day 29 to Day 35 in Period C.
Drug: Digoxin · Drug: Vemurafenib
Participants received single oral dose of digoxin 0.25 mg tablet on Day 1 and Day 29.
Participants received vemurafenib 960 mg tablet orally BID from Day 8 to Day 35.
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUClast) of Digoxin
AUClast = Area under the plasma-concentration time curve from time zero to the last measurable plasma concentration which is presented in hour\*nanogram per milliliter (hour\*ng/mL). Hour 0 (H0) signified pre-dose sampling.
Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Digoxin
Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC24) of Digoxin
Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Area Under the Plasma Concentration-Time Curve From Time Zero to 168 Hours (AUC168) of Digoxin
Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Maximum Plasma Concentration (Cmax) of Digoxin
Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Time to Maximum Plasma Concentration (Tmax) of Digoxin
Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Terminal Half-Life (t1/2) of Digoxin
Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Apparent Clearance (CL/F) of Digoxin
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
| Milestone | Vemurafenib + Digoxin |
|---|---|
| Started | 29 |
| Completed | 29 |
| Not completed | 0 |
| Milestone | Vemurafenib + Digoxin |
|---|---|
| Started | 29 |
| Completed | 28 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | Vemurafenib + Digoxin |
|---|---|
| Started | 28 |
| Completed | 27 |
| Not completed | 1 |
| Withdrew: Death | 1 |
AUClast = Area under the plasma-concentration time curve from time zero to the last measurable plasma concentration which is presented in hour\*nanogram per milliliter (hour\*ng/mL). Hour 0 (H0) signified pre-dose sampling.
| hour*ng/mL | Period A (Digoxin) | Period C (Digoxin + Vemurafenib) |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUClast) of Digoxin | 14.9 ± 4.22 | 27.7 ± 10.6 |
| hour*ng/mL | Period A (Digoxin) | Period C (Digoxin + Vemurafenib) |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Digoxin | 18.5 ± 4.64 | 35.4 ± 4.16 |
| hour*ng/mL | Period A (Digoxin) | Period C (Digoxin + Vemurafenib) |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC24) of Digoxin | 7.73 ± 1.86 | 10.6 ± 2.9 |
| hour*ng/mL | Period A (Digoxin) | Period C (Digoxin + Vemurafenib) |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to 168 Hours (AUC168) of Digoxin | 18.2 ± 4.85 | 29.7 ± 9.62 |
| ng/mL | Period A (Digoxin) | Period C (Digoxin + Vemurafenib) |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of Digoxin | 1.36 ± 0.408 | 1.99 ± 0.562 |
| hours | Period A (Digoxin) | Period C (Digoxin + Vemurafenib) |
|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Digoxin | 1 (0.5 to 3) | 1 (0.47 to 2) |
| hours | Period A (Digoxin) | Period C (Digoxin + Vemurafenib) |
|---|---|---|
| Terminal Half-Life (t1/2) of Digoxin | 35 ± 8.67 | 56.4 ± 11 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| liters/hour | Period A (Digoxin) | Period C (Digoxin + Vemurafenib) |
|---|---|---|
| Apparent Clearance (CL/F) of Digoxin | 14.5 ± 4.95 | 7.15 ± 0.808 |
Collected over From Screening to 28 days after the last dose of study treatment or until initiation of another anticancer therapy, whichever occurred first.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period A | — | 0/29 (0%) | 0/29 (0%) |
| Period B | — | 2/29 (6.9%) | 20/29 (69%) |
| Period C | — | 1/28 (3.6%) | 11/28 (39.3%) |
| Event | Period A | Period B | Period C |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 0/29 | 0/29 | 1/28 |
| RashSkin and subcutaneous tissue disorders | 0/29 | 1/29 | 0/28 |
| Upper respiratory tract infectionInfections and infestations | 0/29 | 1/29 | 0/28 |
| Event | Period A | Period B | Period C |
|---|---|---|---|
| RashSkin and subcutaneous tissue disorders | 0/29 | 7/29 | 3/28 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/29 | 5/29 | 2/28 |
| AstheniaGeneral disorders | 0/29 | 1/29 | 4/28 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/29 | 4/29 | 0/28 |
| NauseaGastrointestinal disorders | 0/29 | 3/29 | 0/28 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 0/29 | 3/29 | 0/28 |
| PyrexiaGeneral disorders | 0/29 | 1/29 | 2/28 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/29 | 0/29 | 2/28 |
| HyperkeratosisSkin and subcutaneous tissue disorders | 0/29 | 0/29 | 2/28 |
| Skin papillomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/29 | 2/29 | 0/28 |
| Age, Continuous(years) | Vemurafenib + Digoxin |
|---|---|
| Mean | 47.8 ± 13.7 |
| Sex: Female, Male(Participants) | Vemurafenib + Digoxin |
|---|---|
| Female | 16 |
| Male | 13 |
The record gives a start of Jul 2013, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Digoxin · Vemurafenib